Novo Nordisk is planning a major India launch of its blockbuster weight-loss drug Wegovy, aiming for Rs 8,600 crore in sales within 5–7 years. The company eyes top spot in prescription drug sales with ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...

They have been called miraculous and the fastest way to lose weight. From Wegovy to Mounjaro, here’s how GLP-1 drugs work ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure ...

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...

Almonds, pistachios, and walnuts may help boost GLP-1 thanks to their fiber, protein, and healthy fats. These nutrients work ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

I don’t love it, but I ate exactly how you told me to eat, and that dress zipped right up, no side skin,” Kelly Ripa said.

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive’ ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Type 2 diabetes , chronic kidney disease , and heart disease consist of a range of risk factors. For example, hyperglycemia, ...